ESTRO 2024 - Abstract Book

S862

Clinical - CNS

ESTRO 2024

Heinrich Heine University, Radiation Oncology, Dusseldorf, Germany

Purpose/Objective:

This study aims to retrospectively assess the efficacy and tolerability of hypofractionated irradiation (40 Gy in 15 fractions) as part of a comprehensive treatment approach for relapsed glioblastoma, involving re-induction chemotherapy with temozolomide, and surgery with or without carmustine implant. Advancements in the technical delivery of irradiation have accentuated the role of radiotherapy in multimodal treatment strategies.

Material/Methods:

Patients diagnosed histologically with glioblastoma and who underwent re-irradiation in our institution were included for retrospective analysis. Data encompassing patient characteristics, therapy details, outcomes, and tolerability were compiled and analyzed, with side effects categorized according to the Common Terminology Criteria for Adverse Events (CTCAE).

Results:

A total of 55 patients were eligible for the study. Most participants underwent surgery and re-induction chemotherapy, primarily involving temozolomide. Complications included one instance of higher-grade radiotherapy-related cerebral edema (CTCAE°IV) and a shunt infection. The median overall survival was 10 months, and progression-free survival was 6 months. Factors such as the interval between initial radiation and recurrence, surgical intervention, and patient age were identified as significant predictors of enhanced overall survival. No instances of higher-grade toxicities were observed, though radiotherapy-induced imaging changes were noted in six patients, and one case each of clinically manifest radionecrosis and secondary hematological tumor development were reported.

Conclusion:

The study’s findings affirm the tolerability of hypofractionated re -irradiation (15 X 2.06 Gy) within an intensive multimodal treatment framework. However, there’s a pronounced need for further research to optimize survival outcomes in patients afflicted with relapsed glioblastoma.

Keywords: brain tumor, glioblastoma, radiation therapy

1817

Digital Poster

Validation of a Methylation-based Signature for Subventricular Zone Involvement in Glioblastoma